AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8557961 — intervention group
Group type: COMPARATOR
Intervention: Amiloride+hydrochlorothiazide (2.5/25 mg once a day)
Number of subjects: 41
Study 1810358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 52
Study 1810358 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin
Number of subjects: 52
Study 1810358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine and Dothiepin
Number of subjects: 52
Study 6863363 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous regional guanethidine
Number of subjects: 7
Study 6863363 — intervention group
Group type: COMPARATOR
Intervention: Intravenous regional reserpine
Number of subjects: 7
Study 30548977 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine
Number of subjects: 47
Study 30548977 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol + lorazepam
Number of subjects: 47
Study 30457119 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast motion-including dose reconstruction for proton pencil beam scanning
Number of subjects: 10
Study 30457119 — intervention group
Group type: COMPARATOR
Intervention: 4DCT motion assumption
Number of subjects: 10
Study 26924621 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological mesh reinforcement during stoma closure
Number of subjects: 90
Study 26924621 — intervention group
Group type: COMPARATOR
Intervention: Standard closure without mesh
Number of subjects: 90
Study 23466111 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (supervised yoga training thrice a week for 4 weeks, followed by home practice for 2 months)
Number of subjects: 29
Study 23466111 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (control)
Number of subjects: 29
Study 21565149 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor Residual Spray (IRS)
Number of subjects: 0
Study 21565149 — intervention group
Group type: COMPARATOR
Intervention: Insecticide Treated Bednets (ITN)
Number of subjects: 0
Study 21565149 — intervention group
Group type: COMPARATOR
Intervention: ITN use
Number of subjects: 0
Study 21565149 — intervention group
Group type: COMPARATOR
Intervention: Sleeping under an ITN
Number of subjects: 0
Study 21565149 — intervention group
Group type: COMPARATOR
Intervention: Community participation in environmental and larval habitat management activities
Number of subjects: 0
Study 19300110 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity training (66% of heart rate reserve)
Number of subjects: 39
Study 19300110 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intensity training (33% of heart rate reserve)
Number of subjects: 39
Study 19300110 — intervention group
Group type: COMPARATOR
Intervention: Control (sedentary period)
Number of subjects: 39
Study 17052140 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaire
Number of subjects: 323
Study 17052140 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence interview item
Number of subjects: 323
Study 17052140 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic medication monitoring
Number of subjects: 323
Study 17052140 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-order factor model of adherence
Number of subjects: 323
Study 17052140 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-method models (one method of assessing adherence)
Number of subjects: 323
Study 17052140 — intervention group
Group type: EXPERIMENTAL
Intervention: Models including both self-report and electronic monitoring
Number of subjects: 323
Study 12737331 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (low-level laser therapy)
Number of subjects: 35
Study 12737331 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 35
Study 11059532 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. polyethylene glycol‐treated human immunoglobulin at 200 mg/kg per day
Number of subjects: 451
Study 11059532 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. polyethylene glycol‐treated human immunoglobulin at 400 mg/kg per day
Number of subjects: 451
Study 11059532 — intervention group
Group type: EXPERIMENTAL
Intervention: freeze‐dried sulfonated human immunoglobulin at 200 mg/kg per day
Number of subjects: 451
Study 9080749 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient mandibular bar-retained overdenture on two implants
Number of subjects: 0
Study 9080749 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants in the maxilla splinted by a rigidly cast bar
Number of subjects: 0
Study 9080749 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdenture therapy
Number of subjects: 0
Study 7680544 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 81
Study 7680544 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 81
Study 2439821 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg p.o.)
Number of subjects: 10
Study 2439821 — intervention group
Group type: COMPARATOR
Intervention: Bopindolol (1 mg p.o.)
Number of subjects: 10
Study 29373493 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional sorghum and millet foods (thick porridges and millet couscous)
Number of subjects: 14
Study 29373493 — intervention group
Group type: COMPARATOR
Intervention: Rice, potato, or pasta
Number of subjects: 14
Study 26999639 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV with GF100%
Number of subjects: 8
Study 26999639 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA with GF100%
Number of subjects: 8
Study 26999639 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV with GF0%
Number of subjects: 8
Study 26999639 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA with GF0%
Number of subjects: 8
Study 26999639 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing carbon dioxide extraction by ECMO
Number of subjects: 8
Study 24394187 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B virus (HBV) envelope DNA vaccine
Number of subjects: 0
Study 24394187 — intervention group
Group type: COMPARATOR
Intervention: Control group (without vaccination)
Number of subjects: 0
Study 21628602 — intervention group
Group type: EXPERIMENTAL
Intervention: NAP/ESO tablet (500 mg EC naproxen + 20 mg non-EC esomeprazole magnesium)
Number of subjects: 40
Study 21628602 — intervention group
Group type: COMPARATOR
Intervention: EC naproxen tablet alone
Number of subjects: 40
Study 21628602 — intervention group
Group type: COMPARATOR
Intervention: EC esomeprazole magnesium capsule alone
Number of subjects: 40
Study 21628602 — intervention group
Group type: COMPARATOR
Intervention: EC naproxen tablet + EC esomeprazole magnesium capsule
Number of subjects: 40
Study 20032480 — intervention group
Group type: EXPERIMENTAL
Intervention: Atole (gruel containing protein and energy)
Number of subjects: 0
Study 20032480 — intervention group
Group type: COMPARATOR
Intervention: Fresco (low-energy drink containing no protein)
Number of subjects: 0
Study 20032480 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal supplementation
Number of subjects: 0
Study 20032480 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nutritional status and supplement intake
Number of subjects: 0
Study 18222355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 1778
Study 18222355 — intervention group
Group type: COMPARATOR
Intervention: Moderate statin therapy
Number of subjects: 1778
Study 18222355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive and moderate statin therapy
Number of subjects: 1778
Study 19615315 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Danggui Sini Decoction
Number of subjects: 72
Study 19615315 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol
Number of subjects: 72
Study 15009510 — intervention group
Group type: EXPERIMENTAL
Intervention: Single light pulse (5000 lux for 3 hr)
Number of subjects: 0
Study 15009510 — intervention group
Group type: EXPERIMENTAL
Intervention: Single melatonin pill (5 mg)
Number of subjects: 0
Study 15009510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of light pulse and melatonin
Number of subjects: 0
Study 11587165 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day of oral amlodipine
Number of subjects: 47
Study 11587165 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of amlodipine (baseline) + 5 mg of amlodipine (additional)
Number of subjects: 47
Study 11587165 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of amlodipine (baseline) + 25 mg of hydrochlorothiazide (HCTZ)
Number of subjects: 47
Study 11587165 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of amlodipine (baseline) + 20 mg of benazepril
Number of subjects: 47
Study 9396419 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 512
Study 9396419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study 7988255 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Living Index‐Cancer (FLIC) administered to patients
Number of subjects: 438
Study 7988255 — intervention group
Group type: COMPARATOR
Intervention: Short course of chemotherapy
Number of subjects: 438
Study 3108159 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate in combination with fat emulsions (fat group)
Number of subjects: 0
Study 3108159 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate solutions (carbohydrate group)
Number of subjects: 0
Study 12561621 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention for 3 months
Number of subjects: 47
Study 12561621 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 47
Study 31365976 — intervention group
Group type: EXPERIMENTAL
Intervention: Peramivir
Number of subjects: 129
Study 31365976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 129
Study 31365976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 30126630 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed incision negative pressure therapy (ciNPT)
Number of subjects: 51
Study 30126630 — intervention group
Group type: COMPARATOR
Intervention: Adhesive strips
Number of subjects: 51
Study 26047766 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs (0.315 g per capsule, 3 capsules daily)
Number of subjects: 50
Study 26047766 — intervention group
Group type: COMPARATOR
Intervention: Mineral oil (placebo)
Number of subjects: 50
Study 23465551 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (n = 12)
Number of subjects: 24
Study 23465551 — intervention group
Group type: COMPARATOR
Intervention: No remote ischemic preconditioning (n = 12)
Number of subjects: 24
Study 23465551 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 24
Study 22262230 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 600 mg every 12 hours for 4 days
Number of subjects: 120
Study 22262230 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg every 24 hours for 4 days
Number of subjects: 120
Study 22262230 — intervention group
Group type: COMPARATOR
Intervention: Hydration only (Control group)
Number of subjects: 120
Study 20522656 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive specific care plan with standardised twice yearly consultation
Number of subjects: 1131
Study 20522656 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1131
Study 16929239 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine-enhanced formula (17 g/day)
Number of subjects: 72
Study 16929239 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous enteral formula
Number of subjects: 72
Study 16138795 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care treatment delivered by primary care teams
Number of subjects: 55
Study 16138795 — intervention group
Group type: COMPARATOR
Intervention: Hospital treatment as usual
Number of subjects: 55
Study 11856154 — intervention group
Group type: EXPERIMENTAL
Intervention: Local therapy plus six cycles of chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) followed by tamoxifen 20 mg daily for 5 years
Number of subjects: 45
Study 11856154 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical control population who never received systemic therapy)
Number of subjects: 45
Study 11856154 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with negative axillary lymph nodes
Number of subjects: 45
Study 11856154 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with positive and negative hormone receptor status
Number of subjects: 45
Study 10550090 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised computer-based information system
Number of subjects: 525
Study 10550090 — intervention group
Group type: COMPARATOR
Intervention: General computer-based information system
Number of subjects: 525
Study 10550090 — intervention group
Group type: COMPARATOR
Intervention: Information booklets
Number of subjects: 525
Study 7869147 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral instructions by certified nurse-midwife in addition to written instructions (Group 2, n = 45)
Number of subjects: 100
Study 7869147 — intervention group
Group type: COMPARATOR
Intervention: Written postpartum instructions only (Group 1, n = 55)
Number of subjects: 100
Study 2673079 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg daily dose of hydroxychloroquine sulphate
Number of subjects: 54
Study 2673079 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg daily dose of hydroxychloroquine sulphate
Number of subjects: 54
Study 2673079 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 347232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose hydrolysed milk
Number of subjects: 50
Study 347232 — intervention group
Group type: COMPARATOR
Intervention: Full-cream milk powder (control)
Number of subjects: 50
Study 31025200 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal bisection task with hands near test stimuli
Number of subjects: 0
Study 31025200 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal time estimation task with hands near test stimuli
Number of subjects: 0
Study 31025200 — intervention group
Group type: COMPARATOR
Intervention: Temporal bisection task with hands far from test stimuli
Number of subjects: 0
Study 31025200 — intervention group
Group type: COMPARATOR
Intervention: Verbal time estimation task with hands far from test stimuli
Number of subjects: 0
Study 25966679 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular infiltrations and continuous post-operative intra-articular infusion of local anaesthetics (PIAC group)
Number of subjects: 50
Study 25966679 — intervention group
Group type: COMPARATOR
Intervention: Combined femoral (continuous) and sciatic (single-shot) nerve block (CFNB group)
Number of subjects: 50
Study 25908190 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE/C (facemask protraction after RPE/C)
Number of subjects: 24
Study 25908190 — intervention group
Group type: COMPARATOR
Intervention: RPE (facemask protraction after RPE)
Number of subjects: 24
Study 25037695 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg subcutaneously every 2 weeks (Q2W), with potential up-titration to 150 mg Q2W at week 12 if LDL-C was ≥ 70 mg/dL at week 8.
Number of subjects: 103
Study 25037695 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/day.
Number of subjects: 103
Study 25037695 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W before up-titration at week 12.
Number of subjects: 103
Study 25037695 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection site reactions for Alirocumab.
Number of subjects: 103
Study 25037695 — intervention group
Group type: COMPARATOR
Intervention: Injection site reactions for Ezetimibe.
Number of subjects: 103
Study 21750917 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm F dentifrice
Number of subjects: 30
Study 21750917 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm F plus fTCP dentifrice
Number of subjects: 30
Study 21750917 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,100 ppm F dentifrice
Number of subjects: 30
Study 19574013 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of MMF (mycophenolate mofetil)
Number of subjects: 17
Study 19574013 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg bid of MMF (mycophenolate mofetil)
Number of subjects: 17
Study 17640366 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs of Suicide (SOS) prevention program
Number of subjects: 4133
Study 17640366 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4133
Study 15022114 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 15022114 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy with Gemcitabine
Number of subjects: 0
Study 15022114 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 15015973 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental-fentanyl-sevoflurane
Number of subjects: 20
Study 15015973 — intervention group
Group type: COMPARATOR
Intervention: Propofol-fentanyl-sevoflurane
Number of subjects: 20
Study 15015973 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (in vitro)
Number of subjects: 20
Study 15015973 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (in vitro)
Number of subjects: 20
Study 15015973 — intervention group
Group type: COMPARATOR
Intervention: Propofol (in vitro)
Number of subjects: 20
Study 12500876 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated grooved implants
Number of subjects: 829
Study 12500876 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyapatite grooved and screw implants
Number of subjects: 829
Study 12500876 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated cylinder
Number of subjects: 829
Study 12500876 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated cylinder and grooved implants
Number of subjects: 829
Study 12500876 — intervention group
Group type: COMPARATOR
Intervention: Non-hydroxyapatite-coated implants
Number of subjects: 829
Study 12500876 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated press-fit cylinder
Number of subjects: 829
Study 9249283 — intervention group
Group type: EXPERIMENTAL
Intervention: Jewelweed extract
Number of subjects: 10
Study 9249283 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 10
Study 7970010 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (maximum dosage of 36 mg/d)
Number of subjects: 124
Study 7970010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 3653179 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 22
Study 3653179 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitozantrone
Number of subjects: 22
Study 3653179 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 22
Study 3653179 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-assessment and physician assigned toxicity scores
Number of subjects: 22
Study 30009640 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1% (four times daily for 28 days)
Number of subjects: 130
Study 30009640 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09% (twice daily for 14 days)
Number of subjects: 130
Study 30009640 — intervention group
Group type: COMPARATOR
Intervention: Steroid-antibiotic combination (Control Group 3)
Number of subjects: 130
Study 28440351 — intervention group
Group type: EXPERIMENTAL
Intervention: HyperSPACE (Hyper SPectral Analysis for Characterization in Echography) method applied before and after laser treatment
Number of subjects: 30
Study 28440351 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasonography and elastography
Number of subjects: 30
Study 26234471 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosehip powder (3 capsules/day for 12 weeks)
Number of subjects: 100
Study 26234471 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 identically appearing capsules/day for 12 weeks)
Number of subjects: 100
Study 23940806 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment variables at 4 weeks post injury
Number of subjects: 85
Study 23940806 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater age, greater injury grade, and weight‐bearing status at baseline
Number of subjects: 85
Study 23940806 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater age, weight‐bearing status at baseline, and non‐inversion injury mechanisms
Number of subjects: 85
Study 21605716 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol (ELD)
Number of subjects: 193
Study 21605716 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (ALF)
Number of subjects: 193
Study 18304123 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating heart valve replacement with normothermic bypass without cross-clamping the aorta
Number of subjects: 50
Study 18304123 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating heart valve replacement with cross-clamping the aorta and retrograde coronary sinus perfusion
Number of subjects: 50
Study 18304123 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery with hypothermic bypass and cardioplegic arrest
Number of subjects: 50
Study 16542130 — intervention group
Group type: EXPERIMENTAL
Intervention: CBSM+MAT (n = 76)
Number of subjects: 130
Study 16542130 — intervention group
Group type: COMPARATOR
Intervention: MAT-only condition (n = 54)
Number of subjects: 130
Study 12687385 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily beclomethasone dipropionate (BDP), 400 micro g/day
Number of subjects: 112
Study 12687385 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily beclomethasone dipropionate (BDP), 400 micro g/day
Number of subjects: 112
Study 11124009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based pain service with an acute pain nurse, educational programme, and regular pain intensity measurements
Number of subjects: 400
Study 11124009 — intervention group
Group type: COMPARATOR
Intervention: Before the introduction of the nurse-based pain service
Number of subjects: 400
Study 8639070 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 45
Study 8639070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline
Number of subjects: 45
Study 8639070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45